Share

EORTC abstracts selected at ASCO Annual meeting 2020

5 EORTC abstracts were selected for the ASCO annual meeting that will take place virtually from 29 until 31 May 2020.

Oral sessions

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase 3 trial at 3-year median follow-up.

Alexander M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Mark Haydon, Andrei Meshcheriakov, Muhammad Khattak, Matteo S. Carlino, Shahneen Kaur Sandhu, Susana Puig, Paolo Antonio Ascierto, Alexander Christopher Jonathan Van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert

  • Presentation number: 293097/10000
  • Speaker: Alexander M. Eggermont

MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients

Fatima Cardoso, Laura van ‘t Veer, Coralie Poncet, Josephine Lopes Cardozo, Suzette Delaloge, Jean-Yves Pierga, Peter Vuylsteke, Etienne Brain, Giuseppe Viale, Sherko Kümmel, Isabel T. Rubio, Gabriele Zoppoli, Alastair Mark Thompson, Erika Matos, Khalil Zaman, Florentine Hilbers, Aleksandra Dudek-Perić, Bart Meulemans, Martine J. Piccart-Gebhart, Emiel J. Rutgers

  • Presentation number: 305903/506
  • Speaker: Fatima Cardoso

Posters sessions

Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma. European Organization for Research and Treatment of Cancer (EORTC) Phase 2 trial 1202

Roberta Sanfilippo, Larry Hayward, Jammbe Musoro, Charlotte Benson, Michael Leahy, Umberto Basso, Jean-Yves Blay, Neeltje Steeghs, Ingrid Desar, Nasim Ali, Alice Hervieu, Thway Khin, Sandrine Marreaud, Saskia Litiere, Hans Gelderblom

  • Poster number: 299473
  • Poster presenter: Roberta Sanfilippo

Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): individual patient data (IPD) meta-analysis of three randomised controlled trials (RCTs) with subgroup analyses of age cohorts.

Elisa Fontana, Clizia Zichi, Elizabeth Catherine Smyth, Murielle E. Mauer, Claus Roedel, Emmanouil Fokas, Ralf Dieter Hofheinz, Dirk Arnold, Hans-Joachim hans-joachim Schmoll, Eric Van Cutsem, Karin Haustermans, Alexander Stein, Jean-Pierre Gerard, Thierry Conroy, Claire Jouffroy-Zeller, Markus H. Moehler, Florian Lordick, Irit Ben-Aharon, Massimo Di Maio

  • Poster number: 303821
  • Poster presenter: Elisa Fontana

Online publication

We couldn’t resist comparing central with local RECIST1.1 and with Choi assessment: exploratory analysis of tumor imaging in EORTC STBSG Phase 2 trial 1317 “CaboGIST”

Anastasios Kyriazoglou, Pieter Jespers, Vincent Vandecavaye, Olivier Mir, Bernd Kasper, Zsuzsanna Papai, Jean-Yves Blay, Antoine Italiano,Facundo Zaffaroni, Saskia Litière, Axelle Nzokirantevye, Patrick Schöffski

  • Online publication number: 300919/e23563
Back to news list

Related News

  • EORTC Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia